Related Experiment Video
Updated: May 19, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Miglustat as a therapeutic agent: prospects and caveats
Rosemarie E Venier1, Suleiman A Igdoura
1Department of Biology, McMaster University, Hamilton, Ontario, Canada.
Abstract:
A viable treatment for lysosomal storage disease has been very difficult to attain. One option is pharmacological inhibition of synthetic pathways to reduce substrate accumulations. Miglustat N-butyldeoxynojirimycin (NBDNJ), an inhibitor of glucosylceramide synthase, has shown much promise in clinical trials for the treatment of Type I Gaucher disease. The molecular events invoked by NBDNJ in cell culture and in animal models have not been so definitive. This review discusses the biochemical and molecular impact of NBDNJ as it relates to its potential as a therapeutic drug.
Related Concept Videos
Therapeutic Drug Monitoring: Overview and Classification
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmacogenomics: Identification of New Drug Targets
Antidepressant Drugs: MAOIs and Other Agents
Therapeutic Drug Monitoring: Affecting Factors
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...